NVCT
Price:
$4.81
Market Cap:
$92.93M
Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases. The company was incorporated in 2020 and is based in Fort Lee, New Jersey.[Read more]
Industry
Biotechnology
IPO Date
2022-02-04
Stock Exchange
NASDAQ
Ticker
NVCT
According to Nuvectis Pharma, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 75.76M. This represents a change of -27.07% compared to the average of 103.88M of the last 4 quarters.
The mean historical Enterprise Value of Nuvectis Pharma, Inc. over the last ten years is 65.62M. The current 75.76M Enterprise Value has changed 11.45% with respect to the historical average. Over the past ten years (40 quarters), NVCT's Enterprise Value was at its highest in in the June 2023 quarter at 217.79M. The Enterprise Value was at its lowest in in the September 2021 quarter at 31.60M.
Average
65.62M
Median
58.14M
Minimum
35.59M
Maximum
110.62M
Discovering the peaks and valleys of Nuvectis Pharma, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 110.56%
Maximum Annual Enterprise Value = 110.62M
Minimum Annual Increase = -13.89%
Minimum Annual Enterprise Value = 35.59M
Year | Enterprise Value | Change |
---|---|---|
2023 | 110.62M | 47.61% |
2022 | 74.94M | 110.56% |
2021 | 35.59M | -13.89% |
The current Enterprise Value of Nuvectis Pharma, Inc. (NVCT) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
73.72M
5-year avg
65.62M
10-year avg
65.62M
Nuvectis Pharma, Inc.’s Enterprise Value is less than Replimune Group, Inc. (914.93M), greater than Lyra Therapeutics, Inc. (25.33M), greater than Kronos Bio, Inc. (15.40M), less than Gossamer Bio, Inc. (348.85M), less than Olema Pharmaceuticals, Inc. (506.70M), less than Larimar Therapeutics, Inc. (401.63M), less than Centessa Pharmaceuticals plc (2.07B), less than Orchestra BioMed Holdings, Inc. (185.69M), less than Monte Rosa Therapeutics, Inc. (544.78M), less than NewAmsterdam Pharma Company N.V. (1.29B), less than Inventiva S.A. (220.01M), less than Cullinan Oncology, Inc. (639.85M), less than Compass Therapeutics, Inc. (197.10M), greater than Ikena Oncology, Inc. (43.80M), greater than Aerovate Therapeutics, Inc. (47.10M), less than Eliem Therapeutics, Inc. (0), less than Decibel Therapeutics, Inc. (102.82M), greater than Anebulo Pharmaceuticals, Inc. (39.05M), greater than Werewolf Therapeutics, Inc. (-3607080.00), less than Edgewise Therapeutics, Inc. (2.82B), less than Celcuity Inc. (560.59M), less than C4 Therapeutics, Inc. (303.21M),
Company | Enterprise Value | Market cap |
---|---|---|
914.93M | $952.30M | |
25.33M | $13.81M | |
15.40M | $64.56M | |
348.85M | $173.69M | |
506.70M | $540.89M | |
401.63M | $431.33M | |
2.07B | $2.38B | |
185.69M | $209.45M | |
544.78M | $626.65M | |
1.29B | $1.71B | |
220.01M | $225.82M | |
639.85M | $739.49M | |
197.10M | $227.02M | |
43.80M | $80.59M | |
47.10M | $77.67M | |
0 | $342.68M | |
102.82M | $123.37M | |
39.05M | $40.46M | |
-3607080.00 | $82.44M | |
2.82B | $2.86B | |
560.59M | $476.00M | |
303.21M | $295.77M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Nuvectis Pharma, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Nuvectis Pharma, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Nuvectis Pharma, Inc.'s Enterprise Value?
What is the highest Enterprise Value for Nuvectis Pharma, Inc. (NVCT)?
What is the 3-year average Enterprise Value for Nuvectis Pharma, Inc. (NVCT)?
What is the 5-year average Enterprise Value for Nuvectis Pharma, Inc. (NVCT)?
How does the current Enterprise Value for Nuvectis Pharma, Inc. (NVCT) compare to its historical average?